Catherine M. Engelbert

CIK: 0001796439

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)4 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

RPRX

Royalty Pharma plc

Director

MCD

MCDONALDS CORP

Director

Discretionary Trading P&L

Holdings

Transaction History (4 total)

RPRX
Royalty Pharma plc
Jun 5, 2026
Award(A)
Direct
4.5K shares-
MCD
MCDONALDS CORP
Dec 31, 2025
Award(A)
Phantom Stock
Direct
671 shares at avg. $305.63-
RPRX
Royalty Pharma plc
May 13, 2025
Award(A)
Direct
7.6K shares-
MCD
MCDONALDS CORP
Dec 31, 2024
Award(A)
Phantom Stock
Direct
700 shares at avg. $289.89-

		Type	Shares	Price		Ownership
Jun 5, 2026	RPRX Royalty Pharma plc	Award(A)	4,545	-	$0	Direct
Dec 31, 2025	MCD MCDONALDS CORP	Award(A) Phantom Stock	671	$305.63	-	Direct
May 13, 2025	RPRX Royalty Pharma plc	Award(A)	7,614	-	-	Direct
Dec 31, 2024	MCD MCDONALDS CORP	Award(A) Phantom Stock	700	$289.89	-	Direct

1-4 of 4 transactions

About Engelbert Catherine M.

Engelbert Catherine M. (SEC CIK 0001796439) files insider reports with the SEC as Director of Royalty Pharma plc (RPRX) and Director of MCDONALDS CORP (MCD).

Signal8 holds 4 ownership filings by Engelbert Catherine M., all Form 4s, filed between Jan 3, 2025 and Jun 8, 2026. Those filings report 4 transactions, from Dec 31, 2024 to Jun 5, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Engelbert Catherine M.'s filings is in NEW YORK, NY.

Recent filings by Engelbert Catherine M.

Jun 5, 2026: Grant or award of RPRX shares (Form 4, code A).
Dec 31, 2025: Grant or award of MCD derivative securities (Form 4, code A).
May 13, 2025: Grant or award of RPRX shares (Form 4, code A).
Dec 31, 2024: Grant or award of MCD derivative securities (Form 4, code A).

Other insiders filing for Royalty Pharma plc (RPRX)

Urist Marshall, EVP, Research & Investments
Bassler Bonnie L, Director
Hite Christopher, EVP & Chairman, Partnering
Coyne Terrance P., EVP & CFO
Legorreta Pablo G., CEO, Chairman of the Board
WEATHERMAN ELIZABETH H, Director

How to read Form 4 transaction codes